腹腔镜胃癌D2根治术联合腹腔内热灌注化疗治疗胃癌的疗效研究

目的:探讨腹腔镜下胃癌D2淋巴结根治术联合术后腹腔内热灌注化疗治疗胃癌的临床疗效。方法:选取2010年1月至2013年9月收治的120例胃癌患者作为研究対象,采用前瞻性研究方法随机分为观察组与对照组,观察组行腹腔镜胃癌D2根治术联合术后腹腔内热灌注化疗、术后化疗;对照组行腹腔镜胃癌D2根治术联合术后化疗,观察两组术后并发症、复发率、生存率。结果:观察组术后并发症发生率为26.67%,对照组为25%,两组差异无统计学意义。随访1年、2年,两组复发率、生存率差异无统计学意义。随访3年,观察组复发率为30%,生存率为81.67%;对照组复发率为50%,生存率为58.33%,差异均有统计学意义。结论:腹腔镜胃癌D2根治术联合术后腹腔内热灌注化疗安全、有效不增加术后并发症发生率,且可提高生存率,降低复发率,值得临床推广应用。

Research on clinical effects of laparoscopic D2 radical gastrectomy and intraperitoneal hyperthermic chemotherapy for gastric cancer

Objective:To investigate the clinical effect of laparoscopic D2 radical gastrectomy and postoperative intraperitoneal hyperthermic chemotherapy ( IPHC) for gastric cancer. Methods:A retrospective analysis was conducted on the data of 60 patients ( control group) who underwent laparoscopic D2 radical gastrectomy for gastric cancer and 60 patients ( observation group) who under-went laparoscopic D2 radical gastrectomy combined with IPHC from Jan. 2010 to Sep. 2013. The two groups were given chemotherapy after surgery. The indexes related to the complications,recurrence rate and survival rate were compared between the two groups. Re-sults:The incidence of postoperative complications was 26. 67% in the observation group,the control group was 25%,there was no sta-tistically significant difference. After follow-up for one to two years,the recurrence rate and survival rate were not significantly different. After 3 years,in observation group the recurrence rate was 30%,the survival rate was 81. 67%;in control group the recurrence rate was 50%,the survival rate was 58. 33%,the differences were statistically significant. Conclusions:For gastric cancer,the laparoscopic D2 radical gastrectomy combined with IPHC is safe and effective,dose not increase postoperative complicatios, can increase survival rate and decrease recurrence rate. It is worthy to be popularized in clinical application.